GlaxoSmithKline PLC's Form 4 filing
Wave Life Sciences, Inc. (WVE) · filed Dec 15, 2025
- Accession no.
- 0001999371-25-020336
- Filed
- Dec 15, 2025
- Trade date
- Dec 11, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $27.9M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| GlaxoSmithKline PLCCIK 0001131399 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | Ordinary Shares | PPurchaseAcquired | +1,470,000 | $19.00 | +$27,930,000 | 18,245,691 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.